{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:25:58Z","timestamp":1787095558907,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["Regeneron Pharmaceuticals"],"award-info":[{"award-number":["Regeneron Pharmaceuticals"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Sanofi"],"award-info":[{"award-number":["Sanofi"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In some cases of chronic pruritus, no identifiable primary cause can be found, whether dermatologic, systemic, neurologic, or psychogenic. In such cases, the disease is referred to as CPUO. To date, little qualitative research has been conducted to understand patient perspectives and a patient-centered conceptual disease model (CDM) for CPUO is lacking. The aims of this study were: to explore the signs, symptoms, and impacts that patients associate with CPUO; and to use these qualitative findings to develop a conceptual disease model (CDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Telephone or web-based semi-structured qualitative interviews were conducted with American adults\u2009\u2265\u200918 years old with a clinician diagnosis of CPUO. Participants were identified at five US clinical sites and interviewed between November 2022 and September 2023. Their interview transcripts were coded using ATLAS.ti, and analyzed to determine the main signs, symptoms, and quality of life impacts of CPUO. Health status over the past month was self-rated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 20 participants were predominantly female (70%), and White (50%) or Asian (40%). Their mean (SD) age was 42.7 (22.4) years. Participants were generally single (65%), employed (65%), and in good (70%) to very good health (15%). All participants reported itch. Other common symptoms included raw skin (85%), stinging (70%), burning (70%), and dry or rough skin (70%). Participants declared itch (55%) to be the worst symptom. In terms of domains impacted, participants with CPUO frequently cited day-to-day activities (90%), sleep (80%), and work or school (70%). Participants reported the domain on which CPUO had the worst impact was sleep (59%). A patient-centric CDM was developed based on these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This first non-interventional qualitative study of adults with CPUO has identified, described, and substantiated the symptoms and impacts of CPUO, which will help define key concepts for patients with CPUO. Itch was the disease-defining symptom of CPUO, and sleep disturbance was its main impact. These and other findings could help physicians make informed clinical decisions about CPUO, and help researchers design CPUO studies with appropriate endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01092-3","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:47:33Z","timestamp":1781189253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concept elicitation and development of a patient-centric conceptual disease model in chronic pruritus of unknown origin"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-9149","authenticated-orcid":false,"given":"Michael","family":"Acquadro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-6863","authenticated-orcid":false,"given":"Efstathios","family":"Zikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-8825","authenticated-orcid":false,"given":"Carla Dias","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1985-4826","authenticated-orcid":false,"given":"Karen","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Dubost-Brama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7156-9390","authenticated-orcid":false,"given":"Eilish","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9887-8159","authenticated-orcid":false,"given":"Donia","family":"Bahloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9710-3799","authenticated-orcid":false,"given":"Ella","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2340\/00015555-3164","volume":"99","author":"E Weisshaar","year":"2019","unstructured":"Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Gim\u00e9nez-Arnau AM et al (2019) European S2k Guideline on Chronic Pruritus. Acta Derm Venereol 99:469\u2013506. https:\/\/doi.org\/10.2340\/00015555-3164","journal-title":"Acta Derm Venereol"},{"key":"1092_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2023.04.018","volume":"152","author":"C Zeidler","year":"2023","unstructured":"Zeidler C, Raap U, Witte F, St\u00e4nder S (2023) Clinical aspects and management of chronic itch. J Allergy Clin Immunol 152:1\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2023.04.018","journal-title":"J Allergy Clin Immunol"},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"Cd013128","DOI":"10.1002\/14651858.CD013128.pub2","volume":"1","author":"A Andrade","year":"2020","unstructured":"Andrade A, Kuah CY, Martin-Lopez JE, Chua S, Shpadaruk V, Sanclemente G, Franco JV (2020) Interventions for chronic pruritus of unknown origin. Cochrane Database Syst Rev 1:Cd013128. https:\/\/doi.org\/10.1002\/14651858.CD013128.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1092_CR4","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1097\/itx.0000000000000064","volume":"8","author":"T Ju","year":"2023","unstructured":"Ju T, Labib A, Vander Does A, Yosipovitch G (2023) Therapeutics in chronic pruritus of unknown origin. Itch 8:e64\u2013e. https:\/\/doi.org\/10.1097\/itx.0000000000000064","journal-title":"Itch"},{"key":"1092_CR5","doi-asserted-by":"crossref","unstructured":"US Food and Drug Administration (2022) Patient-focused drug development: selecting, developing, or modifying fit-for purpose clinical outcome assessments. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome. Accessed 3 Feb 2026","DOI":"10.1007\/s40271-022-00607-6"},{"key":"1092_CR6","unstructured":"US Food and Drug Administration (2018) Patient-focused drug development: collecting comprehensive and representative input. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 3 Feb 2026"},{"key":"1092_CR7","unstructured":"ATLAS.ti for Windows. Version 22 (2023) ATLAS.ti scientific software development GmbH, Berlin, Germany. https:\/\/atlasti.com\/. Accessed 30 Jan 2025"},{"key":"1092_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE (2005) Three approaches to qualitative content analysis. Qual Health Res 15:1277\u20131288. https:\/\/doi.org\/10.1177\/1049732305276687","journal-title":"Qual Health Res"},{"key":"1092_CR9","doi-asserted-by":"publisher","first-page":"e20190250","DOI":"10.1590\/0034-7167-2019-0250","volume":"73","author":"J Soratto","year":"2020","unstructured":"Soratto J, Pires DEP, Friese S (2020) Thematic content analysis using ATLAS.ti software: Potentialities for researchs in health. Rev Bras Enferm 73:e20190250. https:\/\/doi.org\/10.1590\/0034-7167-2019-0250","journal-title":"Rev Bras Enferm"},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273:59\u201365","journal-title":"JAMA"},{"key":"1092_CR11","doi-asserted-by":"publisher","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M (2020) A simple method to assess and report thematic saturation in qualitative research. PLoS ONE 15:e0232076. https:\/\/doi.org\/10.1371\/journal.pone.0232076","journal-title":"PLoS ONE"},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A et al (2018) Informing a priori Sample Size Estimation in Qualitative Concept Elicitation Interview Studies for Clinical Outcome Assessment Instrument Development. Value Health 21:839\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014","journal-title":"Value Health"},{"key":"1092_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamadermatol.2023.3251","volume":"159","author":"D Rodriguez","year":"2023","unstructured":"Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Jabbar Lopez ZK, Piketty C, Puelles J (2023) Patient Perspectives on Living With Severe Prurigo Nodularis. JAMA Dermatol 159:1205\u20131212. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3251","journal-title":"JAMA Dermatol"},{"key":"1092_CR14","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/jdv.15107","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira MP, Basta S, Moore J, St\u00e4nder S (2018) Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. J Eur Acad Dermatol Venereol 32:2224\u20132229. https:\/\/doi.org\/10.1111\/jdv.15107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1092_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","volume":"77","author":"L Eckert","year":"2017","unstructured":"Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM (2017) Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol 77:274\u20139e3. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.019","journal-title":"J Am Acad Dermatol"},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13555-017-0192-3","volume":"7","author":"C Jeon","year":"2017","unstructured":"Jeon C, Yan D, Nakamura M, Sekhon S, Bhutani T, Berger T, Liao W (2017) Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review. Dermatol Ther (Heidelb) 7:349\u2013364. https:\/\/doi.org\/10.1007\/s13555-017-0192-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1092_CR17","doi-asserted-by":"publisher","first-page":"adv8488","DOI":"10.2340\/actadv.v103.8488","volume":"103","author":"BR Ferreira","year":"2023","unstructured":"Ferreira BR, Misery L (2023) Psychopathology Associated with Chronic Pruritus: A Systematic Review. Acta Derm Venereol 103:adv8488. https:\/\/doi.org\/10.2340\/actadv.v103.8488","journal-title":"Acta Derm Venereol"},{"key":"1092_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40257-018-0381-6","volume":"19","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Kantor RW, Dalal P, Hickey C, Shaunfield S, Kaiser K et al (2018) A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults. Am J Clin Dermatol 19:759\u2013769. https:\/\/doi.org\/10.1007\/s40257-018-0381-6","journal-title":"Am J Clin Dermatol"},{"key":"1092_CR19","doi-asserted-by":"publisher","first-page":"adv40677","DOI":"10.2340\/actadv.v104.40677","volume":"104","author":"W Jiang","year":"2024","unstructured":"Jiang W, Chen J, Li N, Wang X, Li C (2024) Depression, Anxiety and Suicidal Ideation in Prurigo Nodularis: A Systematic Review and Meta-analysis. Acta Derm Venereol 104:adv40677. https:\/\/doi.org\/10.2340\/actadv.v104.40677","journal-title":"Acta Derm Venereol"},{"key":"1092_CR20","doi-asserted-by":"publisher","first-page":"adv00550","DOI":"10.2340\/00015555-3892","volume":"101","author":"MP Pereira","year":"2021","unstructured":"Pereira MP, Farcas A, Zeidler C, St\u00e4nder S (2021) Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden. Acta Derm Venereol 101:adv00550. https:\/\/doi.org\/10.2340\/00015555-3892","journal-title":"Acta Derm Venereol"},{"key":"1092_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Seiding Larsen L, Burrows K, Belsito DV, Weisshaar E, Diepgen T et al (2020) Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther 37:692\u2013706. https:\/\/doi.org\/10.1007\/s12325-019-01164-5","journal-title":"Adv Ther"},{"key":"1092_CR22","doi-asserted-by":"publisher","first-page":"835675","DOI":"10.3389\/fcell.2022.835675","volume":"10","author":"B Chen","year":"2022","unstructured":"Chen B, Yang J, Song Y, Zhang D, Hao F (2022) Skin Immunosenescence and Type 2 Inflammation: A Mini-Review With an Inflammaging Perspective. Front Cell Dev Biol 10:835675. https:\/\/doi.org\/10.3389\/fcell.2022.835675","journal-title":"Front Cell Dev Biol"},{"key":"1092_CR23","doi-asserted-by":"publisher","unstructured":"Papa V, Li Pomi F, Borgia F, Vaccaro M, Pioggia G, Gangemi S (2023) Immunosenescence and skin: a state of art of its etiopathogenetic role and crucial watershed for systemic implications. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24097956","DOI":"10.3390\/ijms24097956"},{"key":"1092_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2021.07.076","volume":"86","author":"YS Roh","year":"2022","unstructured":"Roh YS, Choi J, Sutaria N, Kwatra SG (2022) Itch: Epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol 86:1\u201314. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.076","journal-title":"J Am Acad Dermatol"},{"key":"1092_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00403-021-02255-6","volume":"314","author":"G Ingrasci","year":"2022","unstructured":"Ingrasci G, El-Kashlan N, Alexis A, Yosipovitch G (2022) Chronic itch in African Americans: an unmet need. Arch Dermatol Res 314:405\u2013415. https:\/\/doi.org\/10.1007\/s00403-021-02255-6","journal-title":"Arch Dermatol Res"},{"key":"1092_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2340\/00015555-0867","volume":"90","author":"HL Tey","year":"2010","unstructured":"Tey HL, Yosipovitch G (2010) Itch in ethnic populations. Acta Derm Venereol 90:227\u2013234. https:\/\/doi.org\/10.2340\/00015555-0867","journal-title":"Acta Derm Venereol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01092-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01092-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01092-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:04:59Z","timestamp":1787094299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01092-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01092-3","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the ethical principles outlined in Good Clinical Practice guidelines. Institutional review board approval of the study protocol and electronic informed consent form was obtained prior to the conduct of all interviews.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MA, CDB, and KB are employees of Evidera who were contracted to conduct the interviews. EZ, ADB, DB and EB are employees of Sanofi and may hold stock or stock options in the company. EM and AB are employees of Regeneron Pharmaceuticals, Inc. and may hold stock or stock options in the company.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"151"}}